Tech start-up Medicai attracts EUR 500,000 investment from D Moonshots and ROCA X

Mihai Cristea 10/12/2019 | 13:57

Medicai, a tech start-up that strives to change the way multidisciplinary medical teams cooperate with their patients through an online platform, received a new investment worth EUR 500,000 in a financing round led by Sacha Dragic, founder of the Superbet group, through the D Moonshots investment fund.

ROCA X, another tech investment fund dedicated to breakthrough ideas, also participated in this financing round. Apart from being an investment fund, ROCA X also provides know-how and access to a wide network of entrepreneurs and specialists. The legal assistance for the transaction was provided by the Bulboaca and Associates law firm.

“The rapid approval in recent months and the feedback received on the platform from physicians, gave our investors and us the required level of trust to take the project to the next level. The fact that we managed to reach in a very short time a number of 150 doctors registered on the platform, and 20% of them use it daily, shows there’s a real demand. We believe in the need to bring a multidisciplinary approach in healthcare, particularly for serious illnesses, but for this to happen we need to give everyone access to a better way to store, transfer, and corroborate medical data.” Said Mircea Popa, founder and CEO of Medicai.

Through the Medicai platform, patients have the means to easily manage the images on their CDs or USB drives and to safely store them for long periods. In the platform, patients have the option of granting access to their files for several doctors. From here, Medicai will integrate the platform with healthcare clinics, enabling them to look at patient files or to collaborate with other clinics. This way, Medicai represents an online database in which doctors can work together, or with their patients, through Cloud, while the AI-based technology will accelerate their efforts.



Close ×

We use cookies for keeping our website reliable and secure, personalising content and ads, providing social media features and to analyse how our website is used.

Accept & continue